NCT03205566View on ClinicalTrials.gov

Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection

PHASE4CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

September 24, 2018

Study Completion Date

September 24, 2018

Conditions
Hiv
Interventions
DRUG

Raltegravir 400Mg Tab

bd for 7 days

DRUG

Lamivudine 150Mg Tablet

\+ Raltegravir 400Mg tablet bd for 7 days

Trial Locations (1)

SE1 9RT

Harrison Wing, Guy's Hospital, London

All Listed Sponsors
lead

Guy's and St Thomas' NHS Foundation Trust

OTHER

NCT03205566 - Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection | Biotech Hunter | Biotech Hunter